Sumitomo Mitsui DS Asset Management Company Ltd Purchases 12,618 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 271,102 shares of the biopharmaceutical company's stock after acquiring an additional 12,618 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Bristol Myers Squibb were worth $16,535,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock valued at $10,743,262,000 after buying an additional 1,373,209 shares during the last quarter. Capital International Investors lifted its stake in Bristol Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after acquiring an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC grew its position in Bristol Myers Squibb by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after acquiring an additional 1,187,231 shares in the last quarter. Norges Bank bought a new stake in Bristol Myers Squibb in the fourth quarter worth approximately $1,989,525,000. Finally, Ameriprise Financial Inc. increased its stake in shares of Bristol Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

BMY stock traded up $1.20 during trading on Tuesday, reaching $47.49. 21,026,627 shares of the stock were exchanged, compared to its average volume of 12,936,246. The stock has a 50 day simple moving average of $47.85 and a 200-day simple moving average of $53.84. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The company has a market capitalization of $96.65 billion, a P/E ratio of 17.79, a price-to-earnings-growth ratio of 1.37 and a beta of 0.38. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. Bristol Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($4.40) EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.22%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Analyst Ratings Changes

A number of brokerages recently issued reports on BMY. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. UBS Group cut their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Argus raised Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Piper Sandler started coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and a consensus price target of $58.00.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president owned 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.07% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.